Octreotide

Neuroendocrine tumors

Surgery

Somatostatin

Radionuclide therapy

Progression-free survival

Interim analysis

Internal medicine

Clinical endpoint

Chemotherapy

Confidence interval

Medicine

Gastroenterology

Randomized controlled trial

New England Journal of Medicine

Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 (177Lu)–Dotatate in patients with advanced, progressive, somatostatin-receptor–positive midgut neuroendocrine tumors.

Phase 3 Trial of <sup>177</sup>Lu-Dotatate for Midgut Neuroendocrine Tumors

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors